Netanel Derovan's most recent trade in Oramed Pharmaceuticals, Inc was a trade of 20,500 Common Stock done . Disclosure was reported to the exchange on May 26, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc | Netanel Derovan | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 20,500 | 149,500 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals Inc | Netanel Derovan | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 81,000 | 129,000 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals Inc | Netanel Derovan | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 30,000 | 48,000 (0%) | 0% | - | Common Stock | |
| Oramed Pharmaceuticals Inc | Netanel Derovan | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Oramed Pharmaceuticals Inc | Netanel Derovan | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2022 | 18,000 | 18,000 (0%) | 0% | - | Common Stock |